Dietrich Guido, Mollenkopf Hans-Joachim, Weber Heinz, Knapp Bernhard, Diehl Klaus-Dieter, Hess Jürgen, Blackkolb Friedrich, Bröker Michael, Kaufmann Stefan H E, Hundt Erika
Chiron Behring GmbH & Co., D-35006, Marburg, Germany.
J Biotechnol. 2002 Jul 3;96(3):259-70. doi: 10.1016/s0168-1656(02)00046-9.
The Mycobacterium bovis BCG vaccine for commercial use is classically produced as surface pellicles by culture on synthetic medium. Under these conditions, reproducibility of the cultures and quality assessment are hampered by slow growth of the bacilli, the formation of bacterial aggregates and a high proportion of dead bacilli after processing and final formulation of the vaccine. Here, we established dispersed cultures of M. bovis BCG in synthetic media in small-scale bioreactors. These cultures allow recording and adjusting of culture parameters and give rise to single bacilli with a high degree of live bacteria. In the murine model, bioreactor-grown M. bovis BCG exhibited slightly stronger replication and persistence than the vaccine produced under the classical conditions. The protective efficacy against challenge with M. tuberculosis was identical for both vaccine preparations.
用于商业用途的牛分枝杆菌卡介苗(BCG)传统上是通过在合成培养基上培养形成表面菌膜来生产的。在这些条件下,由于杆菌生长缓慢、细菌聚集体的形成以及疫苗加工和最终制剂后高比例的死杆菌,培养的可重复性和质量评估受到阻碍。在此,我们在小规模生物反应器中建立了牛分枝杆菌卡介苗在合成培养基中的分散培养。这些培养物允许记录和调整培养参数,并产生具有高活菌比例的单个杆菌。在小鼠模型中,生物反应器培养的牛分枝杆菌卡介苗的复制和持久性略强于传统条件下生产的疫苗。两种疫苗制剂对结核分枝杆菌攻击的保护效力相同。